Coronavirus disease 2019 has developed as a pandemic. Immunization with the introduction of vaccines against COVID-19 seems be the only way to end this pandemic. We report on a case of a kidney donor, who developed minimal change disease (MCD) within 4 days post-vaccination with the SARS-CoV-2 BNT162b2 mRNA vaccine (Pfizer/BioNTech). She donated her kidney to her husband 4 years ago. After receiving the 1st vaccine dose, she presented with nephrotic syndrome, with complete remission 5 days later. She proceeded with the second dose of the BNT162b2 vaccine at the appointed time. Two days later, she presented with a relapse of full-blown nephrotic syndrome with preserved renal function. We performed an ultrasound-guided percutaneous kidney biopsy and the final diagnosis was consistent with minimal change disease. Oral prednisolone was promptly initiated at a dosage of 1 mg/kg daily and complete remission was achieved 10 days later. More data about this rare appearance of de novo glomerular diseases after SARS-CoV-2 vaccination are emerging and should be interpreted rigorously.
【저자키워드】 COVID-19 vaccination, SARS-CoV-2 mRNA vaccines, minimal change disease, kidney donor, de novo glomerulonephritis, 【초록키워드】 COVID-19, Coronavirus disease 2019, Vaccine, BNT162b2 vaccine, pandemic, Diagnosis, renal function, kidney, vaccine dose, oral, disease, SARS-CoV-2 vaccination, BNT162b2 mRNA vaccine, Donor, Pfizer/BioNTech, Prednisolone, second dose, dosage, syndrome, Final, de novo, Complete, performed, receiving, initiated, glomerular, preserved, the SARS-CoV-2, 【제목키워드】 SARS-CoV-2, change, Pfizer/BioNTech,